April 26, 2019 - 9:00am

Health and Human Services Commission, John H. Winters Human Services Complex, Public Hearing Room
701 West 51st St.
Austin, TX 78751

Add to My Calendar

Webcasting Available

This meeting will be webcast. To access the webcast, go to https://hhs.texas.gov/about-hhs/communications-events/live-archived-meetings the day and time of the meeting.

  1. Call to order
  2. Approval of minutes from January 25, 2019 (vote required)
  3. New business:
    Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
    1. Anti-Allergens, oral
    2. Antibiotics, inhaled
    3. Anticoagulants
    4. Antidepressants, other
    5. Antidepressants, selective serotonin reuptake inhibitors (SSRIs)
    6. Antidepressants, tricyclic
    7. Antihyperuricemics
    8. Antiparkinson agents
    9. Antivirals, oral/nasal
    10. Anxiolytics
    11. Beta blockers
    12. Bile salts
    13. Benign prostatic hyperplasia treatments
    14. Bronchodilators, beta agonist
    15. Chronic obstructive pulmonary disease agents
    16. Cough and cold agents
    17. Cytokine and cell-adhesion molecules antagonists
    18. Erythropoiesis stimulating proteins
    19. Glucocorticoids, inhaled
    20. Hereditary angioedema (HAE) treatments
    21. Hypoglycemics, sodium-glucose cotransporter-2 (SGLT2)
    22. Immune globulins, intravenous
    23. Lincosamides/oxazolidinones/streptogramins
    24. Lipotropics, other
    25. Lipotropics, statins
    26. Pulmonary arterial hypertension agents, oral and inhaled
      aa. Pancreatic enzymes
      bb. Pediatric vitamin preparations
      cc. Prenatal vitamins
      dd. Sedative hypnotics
      ee. Sickle cell anemia treatments
      ff. Thrombopoiesis stimulating proteins
      gg. Urea Cycle Disorder, oral
  4. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:
    1. Tolsura / Antifungals, oral
    2. Udenyca / Colony stimulating factors
    3. Symjepi / Epinephrine, self-injected
    4. Tresiba Vial / Hypoglycemics, Insulin and related agents
    5. ZTLido / Neuropathic pain
    6. Inveltys / Ophthalmic, Anti-inflammatories
    7. Cequa / Ophthalmic, Anti-inflammatories/Immunomodulator
    8. Xelpros / Ophthalmic, Glaucoma agents
    9. Lexette / Steroids, Topical very high
    10. Nuzyra Tablet / Tetracyclines
  5. Therapeutic and clinical drug review updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
  6. Executive work session
    Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
  7. Announcements of proposed drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
  8. Retrospective drug utilization review (DUR): Larry Dent, Pharm. D., BCPS, Conduent, LLC
    1. Report on recent retrospective DUR interventions:
      1. Proton pump inhibitors drug use evaluation
      2. Appropriate use of antibiotics
    2. Report on recent retrospective DUR intervention outcomes:
      1. Asthma disease management
      2. Bipolar disease management
      3. Hypertension disease management
    3. Retrospective DUR proposals (vote required)
      1. Mental health disorders management
      2. Anticonvulsant drug use evaluation
  9. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required)
    1. Arikayce (Amikacin liposome inhalation suspension) - new criteria
    2. HAE
    3. Inhaled Antibiotics - new criteria
    4. SGLT2 Inhibitor Agents
    5. Urea Cycle Disorder Agents - new criteria
  10. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. Aerosolized Agents - Metered-Dose Inhalers (MDIs): Anticholinergic drugs
    2. Aerosolized Agents - MDIs: Anti-Inflammatory drugs (Corticosteriods)
    3. Aerosolized Agents - MDIs: Beta2 Agonists (long-acting)
    4. Aerosolized Agents - MDIs: Beta2 Agonists (short-acting)
    5. Antidepressants (oral) - other
    6. Antidepressants (oral) - SSRIs
    7. Fentanyl (Inhalation/Oral/Transdermal)
    8. Platelet aggregation inhibitors
    9. Proton pump inhibitors
  11. Adjourn - Next meeting date: July 26, 2019

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-707-6112 or Maribel.Castoreno@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-meetings

This meeting is open to the public. No reservations are required, and there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Castoreno at 512-707-6112 at least 72 hours before the meeting so appropriate arrangements can be made.